Edgewise Therapeutics reported a Q3 2025 net loss of $40.7 million, a 12% increase from the $36.12 million loss recorded in Q2 2025 and a 19% rise from the $34.1 million loss in Q3 2024. The company’s earnings per share of $‑0.39 beat the consensus estimate of $‑0.40 by $0.01, a modest but noteworthy margin that reflects disciplined cost management amid aggressive pipeline investment.
Research and development expenses climbed to $37.5 million, up $3.9 million from the prior quarter, driven largely by the initiation of a Phase 1 trial of EDG‑15400 and continued activity in the GRAND CANYON cohort for sevasemten. General and administrative costs increased to $9.4 million, a $0.3 million rise that aligns with the company’s expansion of commercial infrastructure in anticipation of a potential launch of sevasemten in Becker muscular dystrophy.
Cash, cash equivalents and marketable securities stood at $563.3 million as of September 30, 2025, giving Edgewise a runway that comfortably exceeds 12 months of operating expenses. The robust liquidity position supports ongoing clinical development and positions the company to fund future milestones without immediate capital raising.
The company highlighted several pipeline milestones: the GRAND CANYON pivotal cohort for sevasemten is progressing toward a Q4 2026 topline, the Phase 2 CIRRUS‑HCM trial for EDG‑7500 remains on track with a Q4 2025 readout, and a Phase 1 trial of EDG‑15400 for heart failure has been launched. CEO Kevin Koch emphasized that “with a strong balance sheet, we continue to make great progress on our cardiac and skeletal muscle programs,” underscoring the company’s confidence in its pipeline and commercial readiness.
Investors reacted positively to the earnings release, with analysts noting the EPS beat as a sign of effective cost control amid heavy R&D spending. The company’s zero revenue for the quarter met analyst expectations, and the strong cash position was highlighted as a key strength in the market’s assessment.
Looking ahead, Edgewise maintains a focus on advancing its lead programs while managing cash burn. The company’s guidance for the next 12 months remains unchanged, reflecting confidence that the current liquidity will support the planned clinical milestones and potential commercial launch activities. The EPS beat and solid cash position suggest that management is balancing investment in pipeline progress with prudent financial stewardship, positioning Edgewise for future regulatory submissions and market entry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.